Improving R-CHOP in diffuse large B-cell lymphoma is still a challenge-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Improving R-CHOP in diffuse large B-cell lymphoma is still a challenge

Published:2019-05 Issue:5 Volume:20 Page:605-606
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Jardin Fabrice

Publisher

Elsevier BV

Subject

Oncology

Reference10 articles.

1. Is now the time for molecular driven therapy for diffuse large B-cell lymphoma?;Di Rocco;Expert Rev Hematol,2017

2. Aggressive lymphomas;Lenz;N Engl J Med,2010

3. Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial;Davies;Lancet Oncol,2019

4. Randomized phase II study of R-CHOP with or without bortezomib in previously untreated patients with non-germinal center B-cell-like diffuse large B-cell lymphoma;Leonard;J Clin Oncol,2017

5. Clinical impact of the cell-of-origin classification and the MYC/BCL2 dual expresser status in diffuse large B-cell lymphoma treated within prospective clinical trials of the German high-grade non-Hodgkin's lymphoma study group;Staiger;J Clin Oncol,2017

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Flow cytometry quantification of tumor-infiltrating lymphocytes to predict the survival of patients with diffuse large B-cell lymphoma;Frontiers in Immunology;2024-01-29

2. Targeting and internalizing PEGylated nanodrugs to enhance the therapeutic efficacy of hematologic malignancies by anti-PEG bispecific antibody (mPEG × CD20);Cancer Nanotechnology;2023-10-06

3. Targeting positive cofactor 4 induces autophagic cell death in MYC-expressing diffuse large B-cell lymphoma;Experimental Hematology;2023-03

4. Chemotherapy delivery time affects treatment outcomes of female patients with diffuse large B cell lymphoma;JCI Insight;2023-01-24

5. Palbociclib enhances the effect of doxorubicin-induced apoptosis in activated B-cell–like diffuse large B-cell lymphoma cells;Anti-Cancer Drugs;2022-10-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3